JAK-Inhibitors - A Story of Success and Adverse Events.

IF 1.7 Q3 RHEUMATOLOGY
Open Access Rheumatology-Research and Reviews Pub Date : 2024-02-26 eCollection Date: 2024-01-01 DOI:10.2147/OARRR.S436637
Rebekka Wlassits, Mathias Müller, Karl H Fenzl, Thomas Lamprecht, Ludwig Erlacher
{"title":"JAK-Inhibitors - A Story of Success and Adverse Events.","authors":"Rebekka Wlassits, Mathias Müller, Karl H Fenzl, Thomas Lamprecht, Ludwig Erlacher","doi":"10.2147/OARRR.S436637","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"16 ","pages":"43-53"},"PeriodicalIF":1.7000,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906274/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Rheumatology-Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OARRR.S436637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

JAK抑制剂--成功与不良事件的故事。
类风湿性关节炎(RA)是一种全身性、慢性、免疫介导的炎症。治疗方法包括传统的合成改善病情抗风湿药(csDMARDs)、生物改善病情抗风湿药(bDMARDs)(如肿瘤坏死因子(TNF)抑制剂(TNFis))和靶向合成改善病情抗风湿药(tsDMARDs)(包括 Janus 激酶抑制剂(JAKinibs))。口服 JAKinibs 在治疗炎症方面的疗效与 bDMARDs 相当,在某些情况下甚至优于 bDMARDs。然而,在临床应用不断增加的同时,也出现了严重的不良反应,包括重大心脏不良事件(MACE)、恶性肿瘤和静脉血栓发作(VTE),导致美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)的卫生当局实施了监管限制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
34
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信